IL1B and multiple sclerosis: In a study of patients with multiple sclerosis, melatonin has been shown to reduce serum concentrations of TNF-α, IL-6, IL-1β, and lipoperoxides, further leading to evidence that it may reduce inflammatory cytokines [35]. Testing melatonin in ICU patients in the past has not shown significant adverse events.